Cuesta ÁM, et al. PLoS One. 2009, 4:e5381. doi: 10.1371/journal.pone.0005381

Sanchez-Martin D, et al.  J. Biol. Chem. 2011, 286:5197-5203. doi: 10.1074/jbc.M110.161927 

Cuesta ÁM, et al. MAbs 2012.. 4:226-32. doi: 10.4161/mabs.4.2.19140

Blanco-Toribio A, et al. MAbs 2013. 5:70-9. doi: 10.4161/mabs.22698

Alvarez-Cienfuegos A, et al. Sci. Rep. 2016. 6:28643. doi: 10.1038/srep28643.

Harwood SL, et al. Oncoimmunology 2018. doi: 10.1080/2162402X.2017.1377874.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...